Sintx Technologies(US:SINT) Globenewswire·2025-10-16 19:45Core Insights - SINTX Technologies has received a new patent from the USPTO for its antimicrobial fabric technology, further solidifying its competitive advantage and expanding its intellectual property (IP) portfolio [1][2] - The new patent complements a previously approved patent for the composition of antimicrobial fiber materials, enhancing SINTX's position in the infection prevention market [2] - The dual patent strategy strengthens SINTX's IP barrier in various applications, including wound dressings, surgical drapes, personal protective equipment (PPE), and clinical surfaces [1][3] Company Developments - The CEO of SINTX, Eric K. Olson, emphasized that the new patent is a significant milestone that broadens the protection of their proprietary silicon nitride technology platform [2] - The company plans to engage in licensing and joint development with partners in the textile, wound care, and PPE sectors, leveraging its dual patent portfolio for flexible collaboration models [3] Market Context - The infection prevention market is estimated to be around $30 billion, covering medical textiles, wound management, and PPE, which is supported by the new patents [3] - There is a pressing need for passive surface-level solutions to combat hospital-acquired infections (HAIs), with approximately 1 in 31 hospitalized patients experiencing an HAI on any given day in the U.S. [3]